

1 **Adverse Outcomes in Pulmonary Tuberculosis patients on Retreatment Regimen: Evaluation**
2 **of Pharmacokinetic Estimates as Risk Indicators**

3

4 Anant Mohan¹, Anuj Bhatnagar², Tarang Gupta¹, Sunita Kanswal¹, Ujjalkumar Das¹,
5 Thirumurthy Velpandian¹, Randeep Guleria¹ and Urvashi B. Singh^{1*}

6

7

8 ¹ All India Institute of Medical Sciences, New Delhi, India

9 ² Rajan Babu Institute of Pulmonary Medicine and Tuberculosis and Hospital, New Delhi, India

10

11 ***Correspondence to:**

12 **drurvashi@gmail.com**

13

14

15 **Key words :** TDM, ATT, Retreatment regimen, Pharmacokinetics

16

17

18

19

20

21

22

23 **Abstract**

24 Patients with pulmonary tuberculosis (PTB) who fail therapy or develop a relapse are initiated
25 on re-treatment regimen. These patients are known to have adverse outcomes. This study
26 aimed to determine the role of plasma levels of Anti-tubercular drugs in treatment outcome.
27 Plasma levels of retreatment regimen drugs [Isoniazid(INH), Rifampicin(RIF), Pyrazinamide(PZA),
28 Ethambutol(EMB), and Streptomycin(STM)] were compared between treatment
29 responsive/cured and treatment failure/not-cured patients. Plasma drug levels were analysed
30 by LC-MS/MS at different time points in 134 PTB patients on retreatment regimen. Of the 134
31 subjects, 108 were cured, 17 patients developed multi-drug resistant TB (MDR-TB), and 9
32 patients remained smear positive at treatment completion (8 months). The two-hour plasma
33 levels (C_{2hr}) (geometric mean) were lower in 'Not Cured' subjects compared to 'Cured' subjects
34 Notably, in the 26 'Not Cured' subjects, C_{2hr} plasma levels after first dose at Day0 were
35 significantly low (INH: 0.86 vs 2.94 $\mu\text{g/ml}$ $p \leq 0.002$, RIF: 0.56 vs 2.55 $\mu\text{g/ml}$ $p \leq 0.003$, PZA: 1.85 vs
36 26.58 $\mu\text{g/ml}$ $p \leq 0.000$ and EMB: 0.72 vs 1.53 $\mu\text{g/ml}$ $p \leq 0.010$). In contrast, STM levels were higher
37 (31.84 vs 18.08 $\mu\text{g/ml}$ $p \leq 0.007$). Based on ROC analysis of the data, therapeutic indicator
38 values for successful treatment outcome were C_{2hr} plasma levels of 10.6 $\mu\text{g/ml}$ for PZA, 1.14
39 $\mu\text{g/ml}$ for RIF, 1.86 $\mu\text{g/ml}$ for INH and 1.24 $\mu\text{g/ml}$ for EMB. Therapeutic failure in PTB patients
40 on retreatment regimen is associated with lower plasma drug levels. Therapeutic drug
41 monitoring would prove useful to maintain drug levels above the minimum cut-off levels for
42 obtaining favourable clinical outcome.

43

44 **Introduction**

45 In cases of relapse after a successful anti-tubercular therapy (ATT), loss to follow-up or
46 treatment failure, and in others who have undergone previous treatment to TB (1), the
47 standardised retreatment regimen consisting of Isoniazid(INH/H), Rifampicin(RIF/R),
48 Pyrazinamide (PZA/Z), Ethambutol(EMB/E) and Streptomycin(STM/S) for 2 months, followed by
49 HRZE for 1 month and HRE for 5 months (2)is shown to render poor outcomes(3-5) and one of
50 the reasons postulated for this retreatment failure in patients with TB is the sub-therapeutic
51 ATT drug levels or their low bioavailability (6-10) that can lead to slower treatment response,
52 acquired drug resistance, and relapse (11, 12) .

53 Monitoring of plasma levels of drugs to tailor patient's regimen, in a strategy called as
54 'Therapeutic Drug Monitoring' (TDM) has shown promising results in reaching requisite
55 treatment goals in PTB patients (13, 14) . Although TDM has been shown to predict clinical
56 outcomes in treatment-naive PTB (12), no study has exclusively monitored drug levels in PTB on
57 a retreatment regimen. TDM may have important implications for improving outcomes in this
58 group of patients. To address this, we evaluated plasma levels of 5 ATT drugs on Day0 (0 and
59 2hrs after first dose) and after 2, 3, 5 & 8 months of initiation of treatment in subjects who
60 were prescribed PTB retreatment regimen.

61

62

63

64 **Results**

65 **Patients, Treatment Regimens and Outcomes:** A total of 134 pulmonary TB patients with past
66 history of TB and ATT medication were enrolled in the study. One hundred twenty one (90.3%)
67 patients agreed to the intermittent ATT schedule. (DOTS as per RNTCP guidelines), while 13
68 (9.7%) preferred the daily regimen. The demographic details and clinical history of the patients
69 is shown in Table 1 and microbiological testing data is shown in Table 2.

70 All 134 patients had a confirmed drug-susceptible PTB at the start of treatment. Of these, 108
71 (80.5%) patients were declared cured of TB and classified as 'Cured'. Nine patients (6.72%) were
72 not TB-free as per microbiological testing or physical examination. Seventeen patients (12.7 %)
73 developed Rif resistance (RR) MDR (Multi-drug-resistant TB) by the end of third month of
74 therapy and were referred for MDR regimen. Taken together, these 26 patients were
75 categorized as 'Not Cured'.

76 **Plasma Drug Levels:** Plasma levels for H, R, Z, E and S were estimated in all patients for time
77 points day0, followed by month 2, 3, 5 and 8 for H, R, E and day0, 2nd month for Z and on day0
78 for S.

79 In the 17 patients who developed RR, plasma levels for H, R, Z, E and S were estimated until 2nd
80 and 3rd month depending on time of MDR diagnosis.

81 A comparison of drug levels between 'cured' and 'not cured' patient groups according to
82 timelines during the treatment is shown in table 3 and figure 1a. Statistically, plasma levels of
83 isoniazid were significantly higher at 0, 2nd, and 5th month time points, rifampicin levels were
84 significantly higher at day0, comparable at month 2nd and higher at 3rd, 5th and 8th months.

85 Pyrazinamide and ethambutol levels were significantly higher at both Day0 and 2nd months. In
86 contrast to the above four drugs, streptomycin levels were found to be significantly higher on
87 day0 in the 'Not Cured' category of patients. Of note, all thirteen patients in the study who had
88 been on daily dosing regimen, were cured after the therapy, while all patients who acquired
89 drug resistance or failed treatment had been on intermittent therapy.

90 **Pharmokinetic variability in patient population:** Plasma concentrations were found to be
91 widely distributed in the patients. Overall, the highest drug concentrations were attained on
92 day0-C_{2hr} time-point after which most peaks declined with time. Compared to the reference
93 values for adults (15) (16), lower average (GM) drug plasma levels were prevalent at all time
94 points in our study population (Table 3 ,figure 2). 22.3 % (27/121) of patients had plasma
95 concentrations within the reference target range. Only 4/26 'not cured' patients had drug levels
96 within these target ranges and each of these patients achieved 'within range' plasma level for a
97 single drug only.

98 **Area under the ROC curve and predictor values for C_{2hr}plasma ATT levels**

99 Plasma drug levels were significantly lower in 'Not Cured' group when compared to the 'Cured
100 Group' for all ATT drugs at C_{2hr} on day0. Hence we analysed the ROC curves for this time point
101 (Table4, Figure3). The area under the ROC curve were the highest for PZA (0.924) followed by
102 INH (0.788) and RIF (0.77). Optimal cut-off values that predict therapeutic indicator drug levels
103 (minimum levels of drugs that when achieved in patient blood would likely predict a positive
104 treatment outcome) are shown in Table 4. PZA (10.6 µg/ml, 86% sensitivity, 87% specificity)
105 emerged as the best discriminating therapeutic indicator for treatment success in this group of
106 patients (Figure 4).

107 **Discussion**

108 There is a paucity of studies discussing adverse outcomes in PTB re-treatment subjects. Here,
109 we report a serial estimation of levels of first-line ATT drugs measured at five time-points
110 during therapy and correlated to disease outcome exclusively in 134 PTB re-treatment patients.

111 We found a subject-wise variability in plasma concentrations of all four TB drugs which is in
112 concordance with many other studies.(9, 15). Majority (68.5%) patients had lower drug
113 concentrations than the reference values(15, 16) . In the 'Not Cured' category, C_{2hr} levels of four
114 ATT drugs remained much below reference target ranges for adults almost at all time points
115 during the therapy, and were significantly lower than levels in 'Cured' patients. Patients with
116 extremely low C_{2hr} ATT levels in plasma on day0 had outcomes such as acquired MDR-TB and
117 treatment failure. Post-hoc analysis showed that patients with statistically significant low drug
118 levels (65%) got acquired drug resistance within three months of enrolment in the study. All of
119 these patients had lower levels in comparison to both cured and not cured patients (Figure 1b).

120 No statistically significant difference in the drug plasma levels of patients on daily dose as
121 compared to those on intermittent dosing was evident; however, the plasma levels were higher
122 in daily dose patients (Figure4). A significant increase in microbiologically defined adverse
123 outcomes in patients on intermittent therapy has been previously reported by Johnston et al.
124 where pooled analysis and meta regression showed that intermittent regimen in ATT was
125 inferior in all 3 outcomes viz. failure, relapse and acquired drug resistance (17). WHO has since
126 2008 recommended daily dosing (2) and country programs too has now implemented daily
127 DOTS therapy (18)

128 Efficacy of first-line ATT has been shown to strongly associate with area under the curve (AUC).
129 AUC derived from 9-time points sampling during the first 24 hrs post-drug administration were
130 predictive of long-term clinical outcomes in PTB patients (12). Microbicidal effects of ATT are
131 best described by AUC:MIC and C_{max}:MIC ratios (19). Such studies require multiple sampling,
132 are stressful to TB patients and not practical in resource-limited settings. We collected samples
133 at trough concentrations (C₀) and 2 hour concentrations (C_{2hr}) post drug on day 0, months 2, 3, 5
134 and 8 in order to identify the best indicator time point for single sampling as drug levels at C_{2hr}
135 correlate well with C_{max} and/or AUC (15, 16, 20, 21) . However, the possibility that low C_{2hr}
136 plasma concentrations could be a result of delayed absorption rather than a low peak
137 concentration and could miss the actual peak concentration C_{max} (21) cannot be ruled out.

138 Instead of using predetermined C_{max} concentrations, we first enrolled patients randomly and
139 dichotomized them based on treatment outcomes (clinical with microbiological findings) at the
140 end of the study. Loss to follow-up in a few patients, inability to provide sputum specimens,
141 undetectable plasma drug levels etc. have caused a few gaps in our data. Patients were
142 encouraged to comply and we sought to include all available data for analysis.

143 Peak drugs levels attained for INH, RIF and PZA reduced with time in our patients in both
144 'cured' and 'not cured' groups, possibly due to individual pharmacokinetic variations, poor
145 drug absorption, pre-hepatic metabolism and hepatic enzymes induction, drug binding to
146 plasma protein, or drug-drug interactions (22, 23). Rifampicin is reported to be highly bound to
147 plasma proteins in TB patients as well as healthy subjects, leading to a loss in circulating levels,
148 explaining decrease in bioavailability of Rifampicin from 93% to 68% after three weeks of
149 treatment (24-26) . It is tempting to hypothesize that drug-drug interaction is at its minimal on

150 Day0, but may have stronger and complex interactions to compromise drug bioavailability
151 resulting in lower C_{2hr} concentrations subsequently during therapy possibly due to induction of
152 drug metabolism or transporter protein synthesis. Day0- C_{2hr} drug levels for cured patients were
153 higher than subsequent time points except for EMB for which the levels were relatively
154 constant.

155 We also report *therapeutic indicator levels*, the minimal drug plasma level values predicting a
156 positive treatment outcome (Table 4) for all the four ATT drugs. We believe that the day0- C_{2hr}
157 levels especially that of PZA might be useful as a cut-off reference for dosage adjustments for
158 clinicians during therapy and help mitigate adverse events or treatment failure in DOTS
159 Category II patients early on. Similar to our findings, a recent study where drug exposure and
160 MIC were evaluated in PTB patients, PZA levels were shown to be important in predicting poor
161 clinical response suggesting the use of PZA and RIF at levels above a threshold value to improve
162 treatment outcomes. However, the inter-play between PZA and RIF may affect the final levels
163 detected.(27)

164 Evaluation of certain other factors which may contribute to patient outcome was beyond the
165 scope of the present study. Improvement in nutritional status and immune response may
166 complement the pharmacotherapy. Low INH concentrations observed in the patients could also
167 be due to the well recognised pharmacogenetic variants with acetylator status (28-30).
168 Another limitation was that we could not delineate the cumulative effects of the drugs or drug-
169 drug interference in the regimen. Our study had some missing data due to missing patient visits
170 (follow-up) and few undetectable drug levels in some patients. These, however, will unlikely
171 impact the overall results obtained.

172 Overall, we conclude that treatment outcomes in pulmonary tuberculosis patients on
173 retreatment regimen are strongly linked to plasma levels of drugs, with low concentrations
174 leading to poor treatment outcomes. Our findings emphasize the importance of therapeutic
175 drug monitoring and dose adjustment to maintain plasma levels above a critical threshold.

176

177 **Methods and Materials**

178 **Ethics:** This study was done at the All India Institute of Medical Sciences (AIIMS), New Delhi,
179 India from 2012-2014 and approved by the Institutional Ethics Committee, AIIMS (IEC/NP-
180 251/2012&RP-22/2012)

181 **Patients :** Patients diagnosed with drug susceptible PTB (and no other co-morbidities), aged
182 between 15 to 65 yrs and advised the retreatment regimen under National TB Elimination
183 Program (NTEP) (erstwhile Revised National TB Control Program (RNTCP) were included in this
184 study (31) . Informed written consent was obtained from each patient.

185 A detailed demographic data and clinical history was obtained (Table 1), and results of sputum
186 acid-fast stains, cultures and all laboratory data were recorded (Table 2). A brief diagram of the
187 study approach is shown in supplementary figure S1.

188 **Treatment Regimen:** ATT was given as per the prevailing guidelines of the RNTCP at the time of
189 the study (2012-2014) for previously treated TB cases (erstwhile Category II) i.e., INH + RIF+
190 EMB + PZA + injectable STM for 2 months, followed by INH + RIF+ EMB + PZA for 1 month , and
191 INH + RIF+ EMB for 5 months as per the weight bands.(H,5mg/Kg , R,10 mg/Kg , Z,30 mg/Kg ,
192 E,15 mg/Kg, S,15 mg/Kg(in daily regimen) and H,10 mg/Kg , R,10 mg/Kg , Z,30 mg/Kg , E,15

193 mg/Kg, S,15 mg/Kg (intermittent regimen). RNTCP followed intermittent regimen
194 recommended by WHO (2),Clinical follow-up of patients was done at 0 day, weeks 2, 4, 8, 12,
195 20, and 32 (at completion of 8 months). Therapy was not modified during the study.

196 **Sample collection**

197 **Sputum samples:** For AFB smear, MGIT culture and Xpert MTB/RIF assays, 10 ml sputum sample
198 was collected from study subjects at the time of recruitment (Day0) and at the end of 2, 3, 5 and
199 8 months.

200 **Blood samples:** Half ml blood sample was collected for the measurement of baseline drug
201 concentration just before intake of daily dose of ATT and define the trough of drug level, on all
202 days of sample collection. ATT medicines were given under observation of the field worker
203 before breakfast as prescribed, following which the second blood sample (0.5 ml) was collected
204 at 2 hours from the time of drug intake. Blood samples were collected in polypropylene BD
205 vacuutainers containing EDTA and sodium ascorbate. Separated plasma was stored in plain
206 endotoxin free vials at -80⁰C for further use.

207 **Samples processing and AFB-staining:** Samples were processed for decontamination by
208 Modified Petroff's method and stained for acid fast bacilli by Ziehl-Neelson's staining as per
209 standard protocol (32)

210 **Culture for *Mycobacterium tuberculosis*:** Concentrated sediment from decontaminated sample
211 was inoculated in MGIT 960 medium (BD Biosciences) and cultured for *Mycobacterium*
212 *tuberculosis* (MTB) using standard MGITTM method as per manufacturer's instructions (Beckton
213 Dickinson, MD, USA)

214 **Xpert MTB/RIF Assay**

215 Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) was used for detection of MTB and
216 resistance to Rifampicin, as per manufacturer's instructions.

217 **LC-MS/MS and C_{max} determination**

218 Level of drugs in plasma samples were analysed by Liquid chromatography-tandem mass
219 spectrometry (LC-MS/MS) as described previously (33). An Ultra High Performance Liquid
220 Chromatographic system (UHPLC, Thermo Surveyor system, CITY, USA) coupled with a triple
221 quadrupole mass spectrometer API-4000 QTrap fitted with Turbo Ion Spray Ionization (ESI)
222 source (MDS SCIEX, Applied Biosystems, USA) was operated in positive ion mode for separation
223 and detection of drug concentrations of the anti-tuberculosis drugs (H, R, E ,Z and S). Standards
224 were procured from Sigma-Aldrich Ltd, India and the validation of the analytical method was
225 done as per United States Food and Drug Administration (US-FDA) guidelines for bioanalytical
226 method validation (U.S. Food & Drug Administration, 2013).

227 Pharmacokinetic parameters of C_{0hr} were measured for baseline plasma drug concentration and
228 C_{2hrs} for steady state C_{max} plasma concentration. The 2-hour plasma concentrations were
229 compared with the reference C_{2hr} concentrations as described previously (15, 16)

230 **Evaluation of Treatment Response:** Patients were defined as 'cured' if their sputum were AFB-
231 negative within 5 months of treatment and continued to be negative until the end of treatment
232 along with the physician's clinical assessment of TB free status. 'Not Cured' status was defined
233 as presence of a positive AFB smear beyond 5 months of a compliant tuberculosis treatment,
234 presence of a drug-resistant strain during any point of treatment, or a physician's evaluation of

235 symptoms and clinical status after 5 months of treatment compared with the status at
236 diagnosis. (31)

237 **Statistical Analysis:** Data were recorded and analysed using MS-Excel-2007 and SPSS 22.0 for
238 Windows® (SPSS Inc., Chicago, IL, USA). Chi-square tests were used to investigate any
239 association of patient demography with clinical outcomes. Geometric mean (GM) plasma
240 concentrations between the patients groups were compared using one way ANOVA and Mann
241 Whitney U tests. Receiver operator characteristics (ROC) curves were used to study the
242 discriminatory abilities of ATT plasma levels between the two categories and optimal cut off for
243 therapeutic indicator levels (TIL). All tests were two sided, with $P \leq 0.05$ indicating a statistically
244 significant difference.

245

246 **Acknowledgement**

247 We are thankful to our patients for the success of this study. We also thank Mr. Ashish Datt
248 Upadhayay, Statistical Assistant, Department of Biostatistics, AIIMS, New Delhi for the ROC
249 curve analysis.

250 We thank DST-FIST for providing liquid chromatography coupled tandem mass spectroscopy
251 facility for the analysis.

252

253 **References**

254 1. WHO. 2013; updated Dec 2014 and Jan 2020. Definitions and reporting framework for
255 tuberculosis—2013 revision. World Health Organisation Switzerland, Geneva.

- 256 2. WHO. 2010 (updated 2017). Treatment of Tuberculosis Guidelines,4th edition
257 Organisation WH, Geneva, Switzerland.
- 258 3. Jones-López EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo
259 G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R,
260 Elliott AM, Ellner JJ, Smith PG, Mugerwa RD. 2011. Effectiveness of the standard WHO
261 recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a
262 prospective cohort study. PLoS Med 8:15.
- 263 4. Cohen DB, Davies G, Malwafu W, Mangochi H, Joeke E, Greenwood S, Corbett L, Squire
264 SB. 2019. Poor outcomes in recurrent tuberculosis: More than just drug resistance? PLoS
265 One 14.
- 266 5. Sisodia RS, Wares DF, Sahu S, Chauhan LS, Zignol M. 2006. Source of retreatment cases
267 under the revised national TB control programme in Rajasthan, India, 2003. Int J Tuberc
268 Lung Dis 10:1373-9.
- 269 6. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. 1998. Low serum
270 antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113:1178-
271 83.
- 272 7. Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS, Ind PW, McKenna C.
273 1996. Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary
274 tuberculosis. Bmj 313:1543-5.
- 275 8. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow
276 response to tuberculosis treatment in a state control program, Virginia, USA. Emerg
277 Infect Dis 16:1546-53.

- 278 9. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL,
279 Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and
280 pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-
281 infected cohort of adults with tuberculosis from Botswana. *Clin Infect Dis* 48:1685-94.
- 282 10. Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. 2015. Serum Levels
283 of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
284 *Antimicrob Agents Chemother* 60:92-8.
- 285 11. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant
286 tuberculosis not due to noncompliance but to between-patient pharmacokinetic
287 variability. *J Infect Dis* 204:1951-9.
- 288 12. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug
289 concentrations predictive of pulmonary tuberculosis outcomes. *J Infect Dis* 208:1464-73.
- 290 13. Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W,
291 van Soolingen D, Alffenaar JW. 2016. Current status and opportunities for therapeutic
292 drug monitoring in the treatment of tuberculosis. *Expert Opin Drug Metab Toxicol*
293 12:509-21.
- 294 14. Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di
295 Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and
296 PBMCs. *Br J Clin Pharmacol*. 2017 May;83(5):1146-1148. doi: 10.1111/bcp.13196. Epub
297 2017 Jan 18.
- 298 15. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. *Drugs*
299 62:2169-83.

- 300 16. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunegoro H, Ascobat P, Donders R, van
301 Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma
302 concentrations in relation to treatment response in Indonesian pulmonary tuberculosis
303 patients. *Antimicrob Agents Chemother* 57:3614-9.
- 304 17. Johnston JC, Campbell JR, Menzies D. 2017. Effect of Intermittency on Treatment
305 Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis.
306 *Clin Infect Dis* 64:1211-1220.
- 307 18. NTEP (National Tuberculosis Elimination Programme fRNTCP, RNTCP). 2017 March.
308 National Strategic Plan for Tuberculosis: 2017-25 Elimination by 2025. Welfare MoHwF,
309 Ministry of Health with Family Welfare, Nirman Bhawan, New Delhi.
310 <https://tbcindia.gov.in/WriteReadData/National%20Strategic%20Plan%202017-25.pdf>.
- 311 19. Hall RG, Leff RD, Gumbo T. 2009. Treatment of active pulmonary tuberculosis in adults:
312 current standards and recent advances. *Insights from the Society of Infectious Diseases*
313 *Pharmacists. Pharmacotherapy* 29:1468-81.
- 314 20. Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse
315 RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.
316 2019. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line
317 Tuberculosis Drugs in Patients with Tuberculosis. *Clin Pharmacokinet* 58:1445-1454.
- 318 21. Peloquin CA. 1997. Using therapeutic drug monitoring to dose the antimycobacterial
319 drugs. *Clin Chest Med* 18:79-87.
- 320 22. Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. 1987. Influence of the enzyme
321 induction by rifampicin on its presystemic metabolism. *Pharmacol Ther* 33:201-4.

- 322 23. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985.
323 Pharmacokinetics of oral and intravenous rifampicin during chronic administration. *Klin*
324 *Wochenschr* 63:1205-11.
- 325 24. Peloquin CA. 2001. Pharmacological issues in the treatment of tuberculosis. *Ann N Y*
326 *Acad Sci* 953:157-64.
- 327 25. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH,
328 Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA,
329 Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A,
330 Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. 2016. Official
331 American Thoracic Society/Centers for Disease Control and Prevention/Infectious
332 Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible
333 Tuberculosis. *Clin Infect Dis* 63:e147-e195.
- 334 26. Boman G, Ringberger VA. 1974. Binding of rifampicin by human plasma proteins. *Eur J*
335 *Clin Pharmacol* 7:369-73.
- 336 27. Zheng X, Bao Z, Forsman LD, Hu Y, Ren W, Gao Y, Li X, Hoffner S, Bruchfeld J, Alffenaar
337 JW. 2020. Drug exposure and minimum inhibitory concentration predict pulmonary
338 tuberculosis treatment response. *Clin Infect Dis* 18.
- 339 28. Meyer UA, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug
340 metabolism. *Annu Rev Pharmacol Toxicol* 37:269-96.
- 341 29. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ,
342 Aarnoutse RE. 2013. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian
343 patients. *Antimicrob Agents Chemother* 57:3208-13.

- 344 30. Aarnoutse R. 2011. Chapter 18: Pharmacogenetics of Antituberculosis Drugs, vol vol 40.
345 Basel, Karger.
- 346 31. NTEP (National Tuberculosis Elimination Programme fRNTCP, RNTCP). 2016. Technical
347 and Operational Guidelines for TB Control in India Directorate General of Health
348 Services MoHaFW, Nirman Bhawan, Central TB Division, New Delhi - 110001.
- 349 32. RNCTP. April 2009. Training Manual for Mycobacterium tuberculosis Culture & Drug
350 susceptibility testing. Directorate General of Health Services MoHaFW, Nirman Bhawan,
351 Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi 110011,
- 352 33. Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. 2016.
353 Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected
354 Indian children. Int J Tuberc Lung Dis 20:666-72.

355

356

357

358

359

360

361

362

363

Tables

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

Table 1: Basic Demographic and Clinical Details of Study Population

	Characteristics	Statistics	Total (n*)
388	Age		
389	Age (years)	33.5 _± 12.5 (15-65)	131
390	Gender		
391	Male	87 (64.9%)	134
392	Female	47 (35.1%)	
393	Retreatment Category		
394	Relapse	77(57.5%)	
395	Treatment after Default	18(13.4%)	124
396	Treatment Failure	10(7.5%)	
397	Others	19(14.2%)	
398	Smoking History		
399	Non Smoker	73(54.5%)	
400	Ex Smoker	18(13.4%)	117
401	Smoker	26(19.4%)	
402	MSI ** - Ex Smokers	219.47 _± 265.63	
403	MSI** - Smokers	391.78 _± 810.34	
404	Other History		
405	Alcohol intake	44(32.8%)	116
406	Family History of TB	19(14.2%)	
407	Clinical Data –Symptoms		
408	Cough	98(73.1%)	118
409	Fever	65(48.5%)	114
410	Dyspnea	66(49.3%)	117
411	Expectoration	60(44.8%)	112
412	Hemoptysis	28(20.9%)	114
413	Night Sweats	16(11.9%)	111
414	Weight Loss	91(67.9%)	118
415	Loss of appetite	90(67.2%)	117
416	Diarrhea	6(4.5%)	112
417	BMI*** (mean _± SD) kg/m ²	17.9 _± 3.6 (10.6-31.8)	78
418	ATT schedule during study		
419	Daily	13(9.7%)	134
420	Intermittent	121(90.3%)	

410 Data are presented as absolute numbers, percentage (%) or mean (±SD).

411 *number of data available/recorded

412 **MSI- Mean Smoking Index –Calculated as multiplicationof the average number of cigarettes
413 smoked per day with duration (in years) .

414 ***BMI, Body Mass Index (weight in kilograms divided by the square of the height in meters)

415

416

417

Table 2: PTB DOTS Category II Patients – Microbiological Diagnosis Details

418

419	Test	Time Point (month)	Tested (n)	Positive (n)	Negative (n)	MDR (n)
420		0	132 [§]	105 (79.55%)	27(20.45%)	0
421	AFB Smear*	2	83	9 (10.84%)	74(89.16%)	4
422		3	79	8 (10.13%)	71(89.87%)	17**
423		5	81	26 (32.10%)	55(67.90%)	
		8	47	2 (4.26%)	45(95.74%)	
423	MGIT Culture***	0	133 [§]	88 (66.17%)	45(33.83%)	

424 *AFB, acid-fast bacilli

425 **Cumulative number of patients

426 ***MGIT Mycobacteria Growth Indicator Tube

427 [§] For One patient MGIT was not done and in two patients AFB smear data was missing

428

429

430

431

432

433

434

435 **Table 3: Plasma drug levels at 2 hrs post administration of ATT in DOTS category II PTB**
 436 **patients**

437	438 Drug	439 Time Point (month)	Cured		Not Cured		p value
			n*	Plasma levels (µg/ml)**	n*	Plasma levels (µg/ml)**	
440	ISONIAZID	0	87	2.94(0.161-12.80)	17	0.86(0.06-8.27)	0.002 [§]
441		2	68	1.56(0.019-9.89)	14	0.58(0.14-3.07)	0.009 [§]
442		3	67	1.46(0.0331-12.30)	8	0.55(0.05-4.84)	0.172
443		5	51	1.97(0.0934-13.90)	9	0.24(0.00-2.94)	0.031 [§]
444		8	36	1.00(0.0352-6.75)	3	0.25(0.02-1.01)	0.283
445	RIFAMPICIN	0	79	2.55(0.00268-20.20)	16	0.56(0.05-12.70)	0.003 [§]
446		2	54	1.26(0.0802-14.80)	9	1.31(0.19-9.01)	0.689
447		3	55	1.44(0.0017-23.30)	5	0.29(0.01-1.49)	0.124
448		5	46	1.39(0.00384-37.50)	8	0.24(0.04-2.87)	0.144
449		8	31	1.32(0.0643-25.50)	3	0.25(0.06-1.68)	0.380
450	PYRAZINAMIDE	0	88	26.58(1.03-81.60)	15	1.85(0.06-30.50)	0.000 [§]
451		2	71	17.72(0.105-181.0)	14	1.01(0.04-6.43)	0.002 [§]
452	ETHAMBUTOL	0	88	1.53(0.0803-11.80)	17	0.72(0.18-2.15)	0.010 [§]
453		2	70	1.47(0.115-18.00)	14	0.66(0.16-2.19)	0.043 [§]
454		3	68	1.56(0.0365-19.80)	8	1.11(0.22-5.07)	0.332
455		5	53	1.18(0.0676-22.90)	9	0.25(0.03-2.38)	0.137
456		8	36	1.56(0.00813-22.50)	3	0.64(0.08-3.26)	0.344
457	STREPTOMYCIN	0	83	18.08(0.059-73.60)	19	31.84(1.87-100.00)	0.007 [§]

454 Time point 0 represents day of initiation of therapy.

455 *number of data available/recorded

456 ** C2hr data from subjects (on intermittent regimen) was log transformed and is presented as
 457 the geometric mean along with range (minimum-maximum) in µg/ml

458 §Values indicate significant differences between cured and not cured groups (P ≤0.05) by one
 459 way ANOVA

460

Table 4. Receiver operator characteristics (ROC) values for plasma levels of ATT in PTB patients on Retreatment regimen

ATT Drug	n	Area under the Curve	[95% CI]	Optimal Cut off * (µg/ml)	Sensitivity	Specificity
ISONIAZID	104	0.788	[0.67-0.90]	1.86	0.71	0.82
RIFAMPICIN	95	0.770	[0.65-0.89]	1.14	0.77	0.75
PYRAZINAMIDE	103	0.924	[0.84-1.00]	10.6	0.86	0.87
ETHAMBUTOL	105	0.712	[0.60-0.83]	1.24	0.60	0.76
STREPTOMYCIN	102	0.684	[0.54-0.83]	38.0	0.63	0.64

468

469 Table shows accuracy of area under the curve for C2hr plasma levels of ATT in PTB patients on
470 retreatment regimen

471 *Optimal cut off values (column 4) or Therapeutic indicator levels (minimum plasma drug
472 concentrations that predict a positive treatment outcome ('Cured') in the study population).

473

474

475

476

477

478

479

480

481

482

483

484

485 **Figure legends**

486 **Figure 1: Serum levels (ug/ml) at different time points for Category II retreatment regimen**
487 **drugs in PTB patients**

488 Figure 1: a). ATT Plasma levels in Cured and Not Cured PTB patient groups. **b)** ATT Plasma levels
489 in Cured, Rifampicin resistant (RR)MDR and Rifampicin sensitive (RS)Not Cured- groups. X axis
490 shows time points of drug administration i.e. day 0, 2 month, 3 month, 5 month and 8 month
491 (0, 2, 3, 5 and 8 - fig1a) or day 0,2nd month and 3rd month (0, 2 and 3 -fig1b). Y-axis shows
492 geometric mean of plasma drug concentrations ($\mu\text{g/ml}$) of INH, RIF, PZA, EMB and STM as
493 measured by HPLC-MS in patient blood samples after 2hrs of drug ingestion on day 0.
494 Pyrazinamide is shown for 2 months and streptomycin $C_{2\text{hr}}$ levels are shown for day 0 time
495 point as per the treatment regimen.

496 Solid line shows data from Cured subjects and dotted line shows data from Not-cured patients.
497 + represents therapeutic indicator levels i.e. Oday- $C_{2\text{hr}}$ levels required for a successful treatment
498 outcome from cut off predicted from ROC analysis . Statistical significance is as shown in Table
499 3.

500 **Figure 2. Pharmacokinetic variability of isoniazid, rifampicin, pyrazinamide and ethambutol**
501 **in PTB patients on retreatment regimen at Day0- $C_{2\text{hr}}$.**

502 Figure 2. Figure shows the percentage of patients with very low, low and target (high) serum
503 concentrations at $C_{2\text{hr}}$ on Day0 of drug dose administration in 'cured' and 'not cured' groups for
504 isoniazid, rifampicin, pyrazinamide and ethambutol .

505 Values are in comparison to adult reference ranges as reported previously (17) (18)

506 Target ranges: H- 3–6 µg/ml , R- 8–24 µg/ml , Z- 20-50 µg/ml and E- 2–6 µg/ml (17)

507 Low plasma concentrations: H < 3µg/ml , R < 8µg/ml , Z < 35 µg/ml and E < 2 µg/ml .

508 Very low plasma concentrations: H < 1.5µg/ml , R < 4µg/ml , Z < 20 µg/ml and E < 1 µg/ml

509 (18)

510 **Figure 3: ROC Analysis of ATT drugs in PTB patients onretreatment regimen**

511 Figure 3: Figure shows ROC curve analysis of Day0-C_{2hr} plasma levels of ATT-drugs, isoniazid

512 (INH), rifampicin (RIF), pyrazimanide (PZA), ethambutol (EMB) and streptomycin (STM) in PTB

513 patients on retreatment regimen. Values are as given in table 4.

514 **Figure 4: Daily vs intermittent regimen in PTB patients.**

515 Figure 4: Plasma levels of ATT drugs INH, RIF, PZA, EMB and STM at different time points of

516 Daily vs Intermittent/Alternate Day regimen in PTB patients. X axis shows time points of drug

517 administration i.e. day 0, 2 month, 3 month, 5 month and 8 month (0, 2, 3, 5 and 8).Y-axis

518 shows Geometric Mean of plasma drug concentration (µg/ml) as measured by LC-MS in patient

519 blood samples after 2hrs of drug ingestion. Solid line (—●—) represents plasma levels of daily

520 regimen subjects while intermittent regimen patient data is shown by a dashed line (—▲—).*

521 denotes statistical significance $p \leq 0.05$ Pyrazinamide is shown for upto 2 months and

522 streptomycin C_{2hr} levels are shown for Day0

523 **Figure S1: Study Approach:**

524 Figure illustrates a schematic design of the study from patient enrolment until statistical

525 analysis

526

Figures

527

528

529

530

531

532

533

534

535

536

537

538

539


540

541

542


543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566

Fig 1




567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594

Fig 2




595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631

Fig 3



632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656

Fig 4



657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674

Fig S1

